Advances in the research of anti-organ fibrosis drugs
10.16438/j.0513-4870.2020-0392
- VernacularTitle:抗器官纤维化药物研究进展
- Author:
Qiang REN
;
Lu-yong ZHANG
;
Zheng LI
- Publication Type:Research Article
- Keywords:
fibrosis;
organ fibrosis;
treatment strategy;
antifibrotic drug;
cellular signal transduction;
mechanism
- From:
Acta Pharmaceutica Sinica
2020;55(11):2510-2528
- CountryChina
- Language:Chinese
-
Abstract:
Fibrosis is a pathological process characterized by tissue scars and can occur in many organs of the human body. Organ fibrosis is manifested by increased fibrous connective tissue and reduced parenchymal cells in organ tissues, which can lead to destruction of organ structures and reduced function, which seriously endangers human health. Current strategies for treating organ fibrosis include: blocking the transforming growth factor-β1 (TGF-β1)/Smad signaling pathway, anti-inflammatory, regulating the sphingosine kinase 1/sphingosine-1-phosphate (SK1/S1P) signaling pathway, antagonizing vasoactive peptide receptors, enzyme inhibitors, kinase inhibitors, inhibitors of cellular signaling pathway, regulation of metabolic pathways, and mesenchymal stem cell therapy. In the review, the treatment strategies for organ fibrosis and the latest developments in the research of anti-organ fibrosis drugs are summarized to provide a reference for the development of anti-organ fibrosis drugs.
